Biotech Intel



IntelGenx Technologies Corp.
Latest Comments
image_pdfimage_print

BlueOcean in position to tap three huge markets with antioxidant


February 21, 2017
| February 21, 2017

BlueOcean NutraSciences Inc. (TSXV: BOC) announced that it will restart its dormant algae gas infusion subsidiary targeting commercial Omega-3 and […]


IntelGenx takes migraine medication “head-on”


December 22, 2016
| December 22, 2016 | 1 Comment

The term a “bitter pill to swallow” may have been used as a figure of speech since the 17th century, […]


BlueOcean to tap “three huge markets” with the benefits of cannabis and sea


December 14, 2016
| December 14, 2016 | 1 Comment

BlueOcean NutraSciences Inc. (TSXV: BOC) has developed a science-based approach to leverage its current access to 63 retail stores and […]


 

André Godin on the IntelGenx license for Tadalafil erectile dysfunction dosing patent


December 06, 2016
| December 06, 2016

Andre Godin, Executive Vice President and CFO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT), in an interview with […]


IntelGenX changing delivery of famous erectile dysfunction drug


November 22, 2016
| November 22, 2016 | 4 Comments

IntelGenX Technologies Corp. (TSXV: IGX | OTCQX: IGXT) announced the signing of a binding term sheet for a license to […]


The CASL Fines are Starting to Pile Up


November 02, 2016
| November 02, 2016 | 4 Comments

The CRTC recently rolled out another conviction under CASL. Here are the barebones of CASL compliance from a video interview […]


IntelGenx Technologies Corp.